Genentech

#Breaking: Pivotal Phase III results in previously treated KRAS G12C-mutated non-small cell lung cancer presented as an ESMO late-breaker and simultaneously published in the @NEJM. Learn more about our commitment to advancing innovation in #LungCancer:

#Breaking: At @ASNKidney #KidneyWk, we presented positive interim Phase III results of our investigational treatment for IgA nephropathy (IgAN), a chronic and progressive kidney disease. Learn more:

#Breaking: At the joint ACTRIMS-ECTRIMS meeting this week, we're presenting new data in MS and MOGAD. We remain committed to developing innovative medicines for patients with neurological diseases. #MSToronto2026 Learn more:

#Breaking: At #ESMO26, we are presenting new data across our broad oncology portfolio, including lung, breast and other cancers, highlighting our continued commitment to advancing innovation for people living with cancer. Learn more:

#Breaking: The @US_FDA has approved our treatment for adults with thyroid eye disease (TED), providing patients with a new option to help address this complex disease. Read more here:

#Breaking: New Phase III one-year data in uveitic macular edema (UME) will be presented at #AAO2026, alongside news that the @US_FDA has accepted our investigational treatment for UME for review. Learn more:

#Breaking: The @US_FDA approved our adjuvant immunotherapy-based regimen in a certain type of stage III colon cancer, which may establish a new post-surgery standard of care. Read more here:

#Breaking: New real-world data in wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion will be presented at the #Euretina26 annual meeting. Learn more:

#Breaking: @NEJM published pivotal Phase III data for our investigational oral therapy in ER+, HER2- advanced or metastatic #BreastCancer. Read more here:

#Breaking: The @US_FDA has accepted for review our investigational BTK inhibitor, for the treatment of both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Learn more:

Today, we broke ground on a $750M expansion in Hillsboro, Oregon, bringing device fill-finish capabilities to our U.S. manufacturing network to support reliable access to medicines and more convenient delivery options for patients:

#Breaking: The @US_FDA has approved our treatment for patients aged 2 and older with childhood-onset idiopathic nephrotic syndrome (INS). This is the first treatment option in 70 years to be approved for people living with this rare kidney disease. Learn more:

#Breaking: Today we announced positive Phase III results of our investigational treatment in IgA nephropathy (IgAN), a rare and progressive kidney disease. Learn more:

#Breaking: Positive Phase II results show our dual GLP-1/GIP receptor agonist demonstrated significant reductions in blood sugar and body weight in people with type 2 diabetes (#T2D) and #obesity or overweight. Learn more:

We’re investing in the science, infrastructure, and talent powering U.S. biotech leadership. Today, we opened the Roche Genentech Innovation Center Boston, a new hub tackling cardiovascular, renal, and metabolic (CVRM) diseases with AI and data:

#Breaking: Our bispecific antibody combination met its primary endpoint for people living with relapsed or refractory follicular lymphoma. Read more:

#Breaking: The @US_FDA has granted priority review for the first potential treatment for myelin oligodendrocyte glycoprotein antibody-associated disease (#MOGAD). Learn more:

Today we announced an expansion of our Hillsboro, OR site with a new device fill-finish facility. This investment reflects our continued commitment to Hillsboro and the region's workforce as we build end-to-end U.S. drug manufacturing capabilities:

Today marks a major milestone: the topping out of our first-ever East Coast manufacturing facility in Holly Springs, NC. The final beam placement reflects our progress and deep commitment to the region’s workforce, community, and long-term potential: